Research Brief
CJC-1295: Research Overview
A long-acting growth-hormone-releasing hormone (GHRH) analog studied in early human and animal work — investigational, not approved, used non-medically, and subject to anti-doping detection.
Last reviewed: June 2, 2026
For Laboratory Research Use Only
Content on this page describes published research findings. LUMEN BASED does not make therapeutic claims. Consult the primary literature and your institutional review board for protocol design. These products are not for human consumption.
What is CJC-1295?
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), engineered for an extended half-life. It is investigational and not approved; it is used non-medically and is monitored in anti-doping programs.
What the research has investigated
Human pharmacology
In healthy adults, single injections produced dose-dependent 2- to 10-fold increases in plasma growth hormone for 6 or more days and sustained IGF-I elevation for 9–11 days, with no serious adverse events reported at the tested doses. [Teichman 2006]
Mechanism (animal)
Daily dosing normalized body weight and skeletal growth in GHRH-knockout mice and increased pituitary growth-hormone expression. [Alba 2006]
Real-world use
An online-forum analysis documented non-medical self-administration (for weight loss, muscle, and skin), with users themselves uncertain about appropriate dosing. [Van Hout 2016]
Anti-doping detection
Analytical methods have been developed to detect CJC-1295 and related GHRH analogs (for example in equine plasma, and via metabolite-based screening), reflecting its status as a doping agent. [Timms 2019; Memdouh 2021]
The state of the evidence
The evidence comprises limited early human pharmacology plus animal data; CJC-1295 is not approved, and it is primarily encountered in non-medical and anti-doping contexts. [Teichman 2006; Van Hout 2016]
For research use only
LUMEN BASED supplies CJC-1295 strictly for laboratory and research use. It is not a drug, supplement, or therapeutic product, is not intended for human or veterinary use, and nothing on this page is medical advice or a claim of clinical benefit. Every reference below links to its primary source on PubMed for independent verification.
Verify the batch you're studying
Each CJC-1295 lot ships with a third-party Certificate of Analysis (HPLC, mass spectrometry, identity confirmation). Pair the batch in your study with the matching COA before publishing or reporting results.
Product currently unavailable.
References
- Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. PubMed
- Alba M et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. PubMed
- Van Hout MC et al. (2016). Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. PubMed
- Timms M et al. (2019). A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. PubMed
- Memdouh S et al. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. PubMed
For Research Use Only. All LUMEN BASED compounds are strictly for in vitro laboratory research by qualified researchers. Not for human or animal consumption. Not approved by the FDA for therapeutic use.